AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

FundNews newsroom brief · 37m ago · 1 min read · via cnbc.com

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.

Originally reported by cnbc.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →

Across the eCorp newsroom network

Trade-News — Santoli: One key tech ETF may signal whether this bull market can keep marching on
Trade-News — Why the yen’s rise to a six-month high could go further
SerbNews — Elon Musk’s Ex Ashley St. Clair on Rejecting a $40 Million NDA and Participating in ‘Musk’ Doc: ‘I Hope the Risk in Trying to Fight Back Helps a Little Bit’
Trade-News — I have two sons. Should I allow one son to build a $400,000 house on my property? I’m not permitted to subdivide the land.

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

More from FundNews

Across the eCorp newsroom network